$3.56
-0.10(-2.73%)
Mkt Cap $205.9K
$3.54
$75.60
52-Week Range
At a Glance
AI-generated6-K
SciSparc Ltd. entered into a Side Letter dated February 12, 2026, with L.I.A. Pure Capital Ltd. modifying the Securities Purchase Agreement for Convertible Notes up to $10,000,000 aggregate principal, including flexible principal up to $2,500,000 for the Initial Note at 90% purchase price, conditioned on SEC registration filing, and offset rights for consulting fees.$205.9K
Market Cap
$927.0K
Revenue
-$12M
Net Income
Employees2
Fundamentals
How The Business Makes Money
SciSparc Ltd., a specialty clinical-stage pharmaceutical company, develops drugs based on cannabinoid molecules. Its drug development programs include SCI-110 for the treatment of Tourette syndrome, obstructive sleep apnea, and Alzheimer's disease and agitation; SCI-160 for the treatment of pain; and SCI-210 for the treatment of autism spectrum disorder and epilepsy. The company has an agreement with Procaps to develop and commercially manufacture SCI-110 and CannAmide, a palmitoylethanolamide oral tablet in soft gel capsule form. It also has an agreement with the Sheba Fund for Health Services and Research to examine the potential role of SCI-210 for the treatment of status epilepticus; and The Israeli Medical Center for Alzheimer's to conduct a phase IIa clinical trial to evaluate the safety, tolerability, and efficacy of SCI-110 in patients with Alzheimer's disease and agitation. The company was formerly known as Therapix Biosciences Ltd. and changed its name to SciSparc Ltd. in January 2021. SciSparc Ltd. was incorporated in 2004 and is headquartered in Tel Aviv-Yafo, Israel.
Industry Biotechnology
Activity
What Changed Recently
Company Profile
CIK0001611746
ISINIL0010951403
CUSIPM82618121
Phone972 3 715777
AddressTower A, Tel Aviv, 6971916, IL
SEC EDGAR